» Articles » PMID: 35716277

Meta Analysis of Bioactive Compounds, MiRNA, SiRNA and Cell Death Regulators As Sensitizers to Doxorubicin Induced Chemoresistance

Overview
Journal Apoptosis
Publisher Springer
Date 2022 Jun 18
PMID 35716277
Authors
Affiliations
Soon will be listed here.
Abstract

Cancer has presented to be the most challenging disease, contributing to one in six mortalities worldwide. The current treatment regimen involves multiple rounds of chemotherapy administration, alone or in combination. The treatment has adverse effects including cardiomyopathy, hepatotoxicity, and nephrotoxicity. In addition, the development of resistance to chemo has been attributed to cancer relapse and low patient overall survivability. Multiple drug resistance development may be through numerous factors such as up-regulation of drug transporters, drug inactivation, alteration of drug targets and drug degradation. Doxorubicin is a widely used first line chemotherapeutic drug for a myriad of cancers. It has multiple intracellular targets, DNA intercalation, adduct formation, topoisomerase inhibition, iron chelation, reactive oxygen species generation and promotes immune mediated clearance of the tumor. Agents that can sensitize the resistant cancer cells to the chemotherapeutic drug are currently the focus to improve the clinical efficiency of cancer therapy. This review summarizes the recent 10-year research on the use of natural phytochemicals, inhibitors of apoptosis and autophagy, miRNAs, siRNAs and nanoformulations being investigated for doxorubicin chemosensitization.

Citing Articles

Understanding Cancer's Defense against Topoisomerase-Active Drugs: A Comprehensive Review.

Sharma N, Bahot A, Sekar G, Bansode M, Khunteta K, Sonar P Cancers (Basel). 2024; 16(4).

PMID: 38398072 PMC: 10886629. DOI: 10.3390/cancers16040680.


mA-modified circARHGAP12 promotes the aerobic glycolysis of doxorubicin-resistance osteosarcoma by targeting c-Myc.

Zhang D, Guo Q, You K, Zhang Y, Zheng Y, Wei T J Orthop Surg Res. 2024; 19(1):33.

PMID: 38178201 PMC: 10768094. DOI: 10.1186/s13018-023-04502-0.

References
1.
Wilson B, Jacob S, Yap M, Ferlay J, Bray F, Barton M . Estimates of global chemotherapy demands and corresponding physician workforce requirements for 2018 and 2040: a population-based study. Lancet Oncol. 2019; 20(6):769-780. DOI: 10.1016/S1470-2045(19)30163-9. View

2.
Mathur P, Sathishkumar K, Chaturvedi M, Das P, Sudarshan K, Santhappan S . Cancer Statistics, 2020: Report From National Cancer Registry Programme, India. JCO Glob Oncol. 2020; 6:1063-1075. PMC: 7392737. DOI: 10.1200/GO.20.00122. View

3.
Cortes-Funes H, Coronado C . Role of anthracyclines in the era of targeted therapy. Cardiovasc Toxicol. 2007; 7(2):56-60. DOI: 10.1007/s12012-007-0015-3. View

4.
Yang F, Teves S, Kemp C, Henikoff S . Doxorubicin, DNA torsion, and chromatin dynamics. Biochim Biophys Acta. 2013; 1845(1):84-9. PMC: 3927826. DOI: 10.1016/j.bbcan.2013.12.002. View

5.
Gammella E, Maccarinelli F, Buratti P, Recalcati S, Cairo G . The role of iron in anthracycline cardiotoxicity. Front Pharmacol. 2014; 5:25. PMC: 3935484. DOI: 10.3389/fphar.2014.00025. View